Brought to you by 
Celladon secures $30mm through Series B round
04 Jan 2006
Executive Summary
Cardiovascular disease start-up Celladon (molecular cardiology) has secured $30mm in a Series B round from new investors and financing co-leaders Kleiner Perkins Caufield & Byers and Domain Associates; partners from both firms joined Celladon's board. Returning participants included Enterprise Partners Venture Capital and Venrock Associates.
Deal Industry
- Medical Devices
- Pharmaceuticals
-
Pharmaceuticals
- Drug Delivery
-
Biotechnology
- Gene Therapy, Cell Therapy
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Celladon secures $30mm through Series B round
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice